Dr. Qiu’s Myeloma Research Laboratory was founded in 2007 at The National Key Lab of Experimental Hematology in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The main emphasis of Dr. Qiu’s research team is to identify the pathogenesis of multiple myeloma and other malignancy of plasma cells. They mainly focus on the genetic heterogeneous and clonal evolution, drug resistance, bone marrow microenvironment and its interaction with tumor cells in the pathogenesis and progression of multiple myeloma.
Dr. Qiu’s research team is a productive team. They have published more than 50 peer-reviewed research papers on myeloma in international journals, such as Blood, J Clinical Invest, Leukemia, Clinical Cancer Res, and Haematologica. They have also published more than 100 papers on myeloma in Chinese journals and got more 10 China patents.
Their long-term goal is to develop novel techniques, drugs and treatments to prolong myeloma patient survival and even cure this disease.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.